STOCK MARKET BSE NSE

No significant benefit of Umifenovir in COVID-19 treatment: Glenmark Pharmaceuticals

Glenmark said that this was the second clinical study after the successful Favipiravir monotherapy trial earlier this year.

Published: 09th October 2020 08:06 PM  |   Last Updated: 09th October 2020 08:06 PM   |  A+A-

Glenn Saldanhaa, Glenmark Pharmaceuticals

Glenmark Pharmaceuticals CEO Glenn Saldanhaa (Photo| Facebook/ Mex Studios)

By PTI

NEW DELHI: Drug firm Glenmark Pharmaceuticals on Friday said the addition of antiviral Umifenovir did not demonstrate any significant clinical benefit over Favipiravir alone in moderate COVID-19 patients.

The clinical study evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy, Glenmark said in a statement. It added that as per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir.

CLICK HERE FOR LIVE UPDATES OF COVID-19

Glenmark said that this was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir.

"These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-19 infection," Monika Tandon Senior VP & Head, Clinical Development, Global Specialty/Branded Portfolio, Glenmark Pharmaceuticals said.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp